The potential anti-cachectic activity of MEK inhibitors was initially suggested by the finding of weight gain in patients with cholangiocarcinoma treated with the MEK inhibitor, selumetinib [63,64]. Here, MAP2K7 is linked to cholangiocarcinoma.